Kirti Ganorkar, CEO of India Business, Sun Pharma
said, “With over 50,000 Covid-19
cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden.” FluGuard will be available in market from this week.
Recently, Hyderabad's Hetero launched the drug under Favivir brand priced at Rs 59 per tablet.
Glenmark (FabiFlu) has priced at Rs 79 per tablet and the yet to be launched Cipla's Ciplenza (around Rs 68 per tablet).
Already a host of other favipiravir brands have hit the market including smaller firms like Jenburkt Pharma, which has priced it competitively.
More than half a dozen favipiravir brands are in market now and the innovator brand Avigan will be launched by Dr Reddy's Laboratories in August. DRL has remained tight-lipped about the pricing.
The pricing pressure in this category is already visible as Glenmark revised its original price (Rs 103 per tablet) to Rs 79 per tablet within a month of the launch.
Analysts felt that the rush to launch the drug is because it is oral and can be taken at home unlike the injectable drugs used in Covid.
In June the Drug Controller General of India (DCGI) approved the use of favipiravir – an antiviral drug developed in Japan and commonly used for treating influenza – for the treatment of mild to moderate cases of COVID-19 in India.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.